Evan A Wells

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4329715/publications.pdf

Version: 2024-02-01

1477746 1719596 9 140 7 6 citations h-index g-index papers 9 9 9 212 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Heparan Sulfate Proteoglycans (HSPGs) Serve as the Mediator Between Monomeric Tau and Its Subsequent Intracellular ERK1/2 Pathway Activation. Journal of Molecular Neuroscience, 2022, 72, 772-791.	1.1	12
2	Critical Molecular and Cellular Contributors to Tau Pathology. Biomedicines, 2021, 9, 190.	1.4	26
3	Media supplementation for targeted manipulation of monoclonal antibody galactosylation and fucosylation. Biotechnology and Bioengineering, 2020, 117, 3310-3321.	1.7	7
4	Rapid Cell Type-Dependent Uptake of 0N4R TAU Monomer is not Solely Heparin Sulfate Proteoglycan Dependen. Biophysical Journal, 2020, 118, 454a.	0.2	O
5	15(V/K) kinetic isotope effect and steady-state kinetic analysis for the transglutaminase 2 catalyzed deamidation and transamidation reactions. Archives of Biochemistry and Biophysics, 2018, 643, 57-61.	1.4	3
6	Strategies to enhance productivity and modify product quality in therapeutic proteins. Current Opinion in Chemical Engineering, 2018, 22, 81-88.	3.8	17
7	Structural Basis for CD4+ T Cell Epitope Dominance in Arbo-Flavivirus Envelope Proteins: A Meta-Analysis. Viral Immunology, 2017, 30, 479-489.	0.6	10
8	Characterization of Human IgG1 Fc Region Stability and Aggregation Propensity. Biophysical Journal, 2017, 112, 492a.	0.2	0
9	Cellular engineering for therapeutic protein production: product quality, host modification, and process improvement. Biotechnology Journal, 2017, 12, 1600105.	1.8	65